Effects of serum neopterin and homocysteine levels on substrate metals protease in patients with coronary heart disease in different branches
XU Xia1, BAI Xiao1, JIA Xiaowei2
1.Department of Clinical Laboratory, Shaanxi Provincial Corps Hospital, Chinese People’s Armed Police Forces, Xi’An 710054, China; 2.Department of Endocrinology, the 309th Hospital of PLA, Beijing 100091, China
Abstract:Objective To investigate the effects of serum neopterin and homocysteine levels on substrate metals protease in patients with coronary heart disease in different branches. Methods 148 coronary heart disease patients were divided into single lesion group and double branch lesion group, multivessel lesions group, 58, 53, and 37 cases, respectively. Blood was sampled to detect Hcy, Np, MMP-2, MMP-9 and TIMP-2 levels. Results Hcy in duble lesion group was significantly higher than in single lesion (P<0.05), Np [(12.45±3.09)nmol/L] and Hcy [(23.71±4.57) μmol/L] in multilesion group showed significant increase than in the groups A and B (P<0.05). MMP-2[(49.83±7.64)ng/L], and MMP-9[(194.81±17.58)ng/L] in double lesion group were significantly higher than in single lesion group (P<0.05), TIMP-2 [(283.70±23.45)ng/L] in double lesion group significantly decreased (P<0.05). MMP-2 [(63.42±8.59)ng/L], MMP-9 [(249.73±24.16) ng/L] and TIMP-2 [(205.61±17.32)ng/L] in multilesion group were significantly different from the single and double lesion groups (P<0.05). Np and MMP-9 showed significant positive correlation (P<0.05), and TIMP-2 showed significantly negative correlation (P<0.05), Hcy and MMP-2 and MMP-9 showed significantly positive correlation (P<0.05), and TIMP-2 showd significantly negative correlation (P<0.05). Conclusions Np and Hcy are closely related to the field of coronary heart disease, which are closely related to MMPs indicating the progression of coronary atherosclerosis.
许霞, 白晓, 贾晓炜. 冠心病不同分支病变对血清新喋呤、同型半胱氨酸及基质金属蛋白酶的影响[J]. 武警医学, 2015, 26(3): 256-258.
XU Xia, BAI Xiao, JIA Xiaowei. Effects of serum neopterin and homocysteine levels on substrate metals protease in patients with coronary heart disease in different branches. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(3): 256-258.
Pita-Fernandez S, Choucino-Fernandez T, Juega-Puig J, et al. A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia [J]. Int J Clin Pract, 2014,25(1):63-71.
[2]
Song I U, Kim J S, Park I S, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson’s disease (PD)[J]. Arch Gerontol Geriatr, 2013, 57(3): 288-291.
[10]
Kotani T, Takeuchi T, Takai S, et al. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-alpha antibody (infliximab) therapy in patients with rheumatoid arthritis[J]. J Pharmacol Sci, 2012, 120(1): 50-53.
[3]
Hou Z H, Lu B, Gao Y, et al. Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography [J]. Acad Radiol, 2013, 20(1): 25-31.
[4]
Gostiljac D, Dordevic P B, Djuric D, et al. The importance of defining serum MMP-9 concentration in diabetics as an early marker of the rupture of atheromatous plaque in acute coronary syndrome [J]. Acta Physiol Hung, 2011, 98(1): 91-97.
Shalia K K, Shah V K, Mashru M R, et al. Matrix metalloproteinase-3 (MMP-3) -1612 5A/6A promoter polymorphism in coronary artery disease in Indian population[J]. Indian J Clin Biochem, 2010,25(2):133-140.
[5]
Mendy V L, Azevedo M J, Sarpong D F, et al. The Association between individual and combined components of metabolic syndrome and chronic kidney disease among African Americans: the Jackson heart study [J]. PLoS One, 2014, 9(7): 815-823
Kuyumcu M E, Yesil Y, Ozturk Z A, et al. The association between homocysteine (hcy) and serum natural antioxidants in elderly bone mineral densitometry (BMD) [J]. Arch Gerontol Geriatr, 2012, 55(3): 739-743.
[8]
Guo C, Zhang S, Zhang J, et al. Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9[J]. Exp Ther Med, 2014, 7(5): 1177-1180.
[9]
Li M, Shi J, Fu L, et al. Genetic polymorphism of MMP family and coronary disease susceptibility: a meta-analysis [J]. Gene, 2012, 495(1): 36-41.
[10]
Kotani T, Takeuchi T, Takai S, et al. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-alpha antibody (infliximab) therapy in patients with rheumatoid arthritis[J]. J Pharmacol Sci, 2012, 120(1): 50-53.
Shalia K K, Shah V K, Mashru M R, et al. Matrix metalloproteinase-3 (MMP-3) -1612 5A/6A promoter polymorphism in coronary artery disease in Indian population[J]. Indian J Clin Biochem, 2010,25(2):133-140.